Rhythm Pharmaceuticals, Inc. (FRA:1RV)
Germany · Delayed Price · Currency is EUR 89.50
+3.00 (3.47%)
At close: Nov 25, 2025
Rhythm Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 174.33 | 130.13 | 77.43 | 23.64 | 3.15 | - | Upgrade | |
Revenue Growth (YoY) | 54.92% | 68.06% | 227.56% | 649.46% | - | - | Upgrade |
Cost of Revenue | 18.48 | 13.37 | 9.3 | 2.13 | 0.6 | - | Upgrade |
Gross Profit | 155.86 | 116.76 | 68.13 | 21.51 | 2.56 | - | Upgrade |
Selling, General & Admin | 175.59 | 144.3 | 117.53 | 92.03 | 68.49 | 46.13 | Upgrade |
Research & Development | 166.48 | 237.96 | 134.95 | 108.63 | 104.13 | 90.45 | Upgrade |
Operating Expenses | 342.07 | 382.26 | 252.48 | 200.66 | 172.61 | 136.58 | Upgrade |
Operating Income | -186.21 | -265.5 | -184.36 | -179.16 | -170.06 | -136.58 | Upgrade |
Interest Expense | -21.42 | -20.6 | -13.89 | -5.2 | - | - | Upgrade |
Interest & Investment Income | 14.72 | 14.71 | 13.95 | 4.03 | 0.45 | 2.58 | Upgrade |
Other Non Operating Income (Expenses) | 9.91 | 11.14 | 0.19 | 0.25 | 100 | - | Upgrade |
EBT Excluding Unusual Items | -182.99 | -260.26 | -184.11 | -180.08 | -69.61 | -134 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -1.04 | - | - | Upgrade |
Pretax Income | -191.89 | -260.26 | -184.11 | -181.12 | -69.61 | -134 | Upgrade |
Income Tax Expense | 0.44 | 0.35 | 0.56 | - | - | - | Upgrade |
Net Income | -192.33 | -260.6 | -184.68 | -181.12 | -69.61 | -134 | Upgrade |
Preferred Dividends & Other Adjustments | 5.39 | 3.97 | - | - | - | - | Upgrade |
Net Income to Common | -197.71 | -264.57 | -184.68 | -181.12 | -69.61 | -134 | Upgrade |
Shares Outstanding (Basic) | 64 | 61 | 58 | 52 | 50 | 44 | Upgrade |
Shares Outstanding (Diluted) | 64 | 61 | 58 | 52 | 50 | 44 | Upgrade |
Shares Change (YoY) | 5.39% | 5.76% | 10.65% | 5.08% | 12.40% | 21.15% | Upgrade |
EPS (Basic) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | -3.04 | Upgrade |
EPS (Diluted) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | -3.04 | Upgrade |
Free Cash Flow | -109.13 | -113.88 | -136.2 | -173.71 | -146.44 | -122.19 | Upgrade |
Free Cash Flow Per Share | -1.71 | -1.87 | -2.36 | -3.33 | -2.95 | -2.77 | Upgrade |
Gross Margin | 89.40% | 89.73% | 87.99% | 90.98% | 81.01% | - | Upgrade |
Operating Margin | -106.81% | -204.04% | -238.10% | -757.92% | -5391.85% | - | Upgrade |
Profit Margin | -113.41% | -203.32% | -238.52% | -766.22% | -2207.10% | - | Upgrade |
Free Cash Flow Margin | -62.60% | -87.51% | -175.91% | -734.87% | -4642.90% | - | Upgrade |
EBITDA | -184.76 | -263.94 | -182.6 | -177.49 | -168.9 | -135.89 | Upgrade |
EBITDA Margin | -105.98% | -202.83% | -235.83% | - | - | - | Upgrade |
D&A For EBITDA | 1.45 | 1.56 | 1.76 | 1.67 | 1.16 | 0.69 | Upgrade |
EBIT | -186.21 | -265.5 | -184.36 | -179.16 | -170.06 | -136.58 | Upgrade |
EBIT Margin | -106.81% | -204.04% | -238.10% | - | - | - | Upgrade |
Revenue as Reported | 174.33 | 130.13 | 77.43 | 23.64 | 3.15 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.